The following information is missing from the Funding section: Publication of this study was supported by Wroclaw Centre of Biotechnology, programme The Leading National Research Centre (KNOW) for years 2014–2018.
Reference
- 1. Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczyjew A, et al. (2018) The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(1): e0190525. https://doi.org/10.1371/journal.pone.0190525 pmid:29304116
Citation: Lange A, Jaskula E, Lange J, Dworacki G, Nowak D, Simiczyjew A, et al. (2018) Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS ONE 13(12): e0209108. https://doi.org/10.1371/journal.pone.0209108
Published: December 6, 2018
Copyright: © 2018 Lange et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.